Base de dados : MEDLINE
Pesquisa : D02.355.601.536.400 [Categoria DeCS]
Referências encontradas : 455 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 46 ir para página                         

  1 / 455 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27662264
[Au] Autor:Deng S; Huang W; Ni X; Zhang M; Lu H; Wang Z; Hu J; Zhu X; Qiu C; Shang D; Zhang Y; Xiong L; Wen Y
[Ad] Endereço:a Institution of National Drug Clinical Trials, The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital) , Guangzhou , China.
[Ti] Título:Pharmacokinetics of guaifenesin, pseudoephedrine and hydrocodone in a combination oral liquid formulation, administered as single and multiple doses in healthy Chinese volunteers, and comparison with data for individual compounds formulated as Antuss®.
[So] Source:Xenobiotica;47(10):870-878, 2017 Oct.
[Is] ISSN:1366-5928
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:1. A new oral liquid formulation combining guaifenesin, pseudoephedrine and hydrocodone is effective in improving the symptoms of common cold. The pharmacokinetic properties of the individual components were evaluated in a randomized, open-label, four-period study in 12 healthy Chinese volunteers following single and multiple doses. The data were compared with data for the individual ingredients in Antuss®. 2. In the single-dose period, exposure levels (AUC and C ) for guaifenesin, pseudoephedrine and hydrocodone increased directly as the dose of the oral liquid formulation increased from 5 to 15 mL. Only minor amounts of guaifenesin and hydrocodone were excreted in urine (∼0.10% and 4.66%, respectively). Pseudoephedrine was mainly excreted unchanged, with 44.95% of the dose excreted in urine within 24 h. After multiple dosing, there was no obvious accumulation of any drug, as assessed by AUC. When considering C , there was a trend toward accumulation of hydrocodone and pseudoephedrine. The pharmacokinetic profiles of guaifenesin and pseudoephedrine in the oral liquid formulation were similar to those in the branded preparation, Antuss®. 3. The newly developed oral liquid formulation combining guaifenesin, pseudoephedrine and hydrocodone was safe and well tolerated and might provide a reliable alternative to the branded formulation for patients with common colds.
[Mh] Termos MeSH primário: Guaifenesina/farmacocinética
Hidrocodona/farmacocinética
Pseudoefedrina/farmacocinética
[Mh] Termos MeSH secundário: Administração Oral
Adulto
Disponibilidade Biológica
Feminino
Voluntários Saudáveis
Seres Humanos
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
495W7451VQ (Guaifenesin); 6YKS4Y3WQ7 (Hydrocodone); 7CUC9DDI9F (Pseudoephedrine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171018
[Lr] Data última revisão:
171018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160924
[St] Status:MEDLINE
[do] DOI:10.1080/00498254.2016.1241451


  2 / 455 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27435233
[Au] Autor:Kolbach-Mandel AM; Mandel NS; Cohen SR; Kleinman JG; Ahmed F; Mandel IC; Wesson JA
[Ad] Endereço:Medical College of Wisconsin, 9200 W Wisconsin Avenue, Milwaukee, WI, 53226, USA.
[Ti] Título:Guaifenesin stone matrix proteomics: a protocol for identifying proteins critical to stone formation.
[So] Source:Urolithiasis;45(2):139-149, 2017 Apr.
[Is] ISSN:2194-7236
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Drug-related kidney stones are a diagnostic problem, since they contain a large matrix (protein) fraction and are frequently incorrectly identified as matrix stones. A urine proteomics study patient produced a guaifenesin stone during her participation, allowing us to both correctly diagnose her disease and identify proteins critical to this drug stone-forming process. The patient provided three random midday urine samples for proteomics studies; one of which contained stone-like sediment with two distinct fractions. These solids were characterized with optical microscopy and Fourier transform infrared spectroscopy. Immunoblotting and quantitative mass spectrometry were used to quantitatively identify the proteins in urine and stone matrix. Infrared spectroscopy showed that the sediment was 60 % protein and 40 % guaifenesin and its metabolite guaiacol. Of the 156 distinct proteins identified in the proteomic studies, 49 were identified in the two stone-components with approximately 50 % of those proteins also found in this patient's urine. Many proteins observed in this drug-related stone have also been reported in proteomic matrix studies of uric acid and calcium containing stones. More importantly, nine proteins were highly enriched and highly abundant in the stone matrix and 8 were reciprocally depleted in urine, suggesting a critical role for these proteins in guaifenesin stone formation. Accurate stone analysis is critical to proper diagnosis and treatment of kidney stones. Many matrix proteins were common to all stone types, but likely not related to disease mechanism. This protocol defined a small set of proteins that were likely critical to guaifenesin stone formation based on their high enrichment and high abundance in stone matrix, and it should be applied to all stone types.
[Mh] Termos MeSH primário: Expectorantes/efeitos adversos
Guaifenesina/efeitos adversos
Cálculos Renais/química
Cálculos Renais/etiologia
Urina/química
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Proteômica
Espectroscopia de Infravermelho com Transformada de Fourier
[Pt] Tipo de publicação:CASE REPORTS; COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Expectorants); 495W7451VQ (Guaifenesin)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170923
[Lr] Data última revisão:
170923
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160721
[St] Status:MEDLINE
[do] DOI:10.1007/s00240-016-0907-4


  3 / 455 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27544751
[Au] Autor:Lin X; Gong R; Li J; Li P; Yu J; Rodrigues AE
[Ad] Endereço:State Key Laboratory of Chemical Engineering, College of Chemical Engineering, East China University of Science and Technology, Shanghai, 200237, China.
[Ti] Título:Enantioseparation of racemic aminoglutethimide using asynchronous simulated moving bed chromatography.
[So] Source:J Chromatogr A;1467:347-355, 2016 Oct 07.
[Is] ISSN:1873-3778
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The separation of aminoglutethimide enantiomers by the continuous multicolumn chromatographic processes were investigated experimentally and theoretically, where the columns were packed with cellulose tris 3,5-dimethylphenyl-carbamate stationary phase (brand name Chiralcel OD) and mobile phase was a mixture of n-hexane and ethanol with monoethanolamine additive. The continuous enantioseparation processes included a synchronous shifting process (SMB) and an asynchronous shifting process (VARICOL), which allowed reducing the column number (here from six-column SMB to five-column VARICOL process). Transport-dispersive model with the consideration of both intraparticle mass transfer resistance and axial dispersion was adopted to design and optimize the operation conditions for the separation of aminoglutethimide enantiomers by SMB process and VARICOL process. According to the optimized operation conditions, experiments were carried out on VARICOL-Micro unit using five-column VARICOL process with 1/1.5/1.5/1 configuration and six-column SMB process with 1/2/2/1 configuration. Products of R-aminoglutethimide (R-AG) enantiomer and S-aminoglutethimide (S-AG) enantiomer with more than 99.0% purity were obtained continuously from extract stream and raffinate stream, respectively. Furthermore, the experiemntal data obtained from five-column VARICOL process were compared with that from six-column SMB process, the feasibility and efficiency for the separation of guaifenesin enantiomers by VARICOL processes were evaluated.
[Mh] Termos MeSH primário: Aminoglutetimida/química
Cromatografia/instrumentação
[Mh] Termos MeSH secundário: Aminoglutetimida/isolamento & purificação
Celulose/análogos & derivados
Etanol
Guaifenesina/química
Guaifenesina/isolamento & purificação
Hexanos
Indicadores e Reagentes
Organofosfatos
Fenilcarbamatos
Estereoisomerismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hexanes); 0 (Indicators and Reagents); 0 (Organophosphates); 0 (Phenylcarbamates); 0O54ZQ14I9 (Aminoglutethimide); 110735-13-2 (cellulose tris-3,5-dimethylphenyl-carbamate); 126-72-7 (tris(2,3-dibromopropyl)phosphate); 2DDG612ED8 (n-hexane); 3K9958V90M (Ethanol); 495W7451VQ (Guaifenesin); 9004-34-6 (Cellulose)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:171008
[Lr] Data última revisão:
171008
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160822
[St] Status:MEDLINE


  4 / 455 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27298495
[Au] Autor:Shabbir A; Shamsi S; Shahzad M; Butt HI; Aamir K; Iqbal J
[Ad] Endereço:Pharmacology Section, Faculty of Pharmacy, The University of Lahore, Lahore, Pakistan.
[Ti] Título:Evaluation of developmental toxicity of guaifenesin using pregnant female rats.
[So] Source:Indian J Pharmacol;48(3):264-9, 2016 May-Jun.
[Is] ISSN:1998-3751
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Guaifenesin possesses expectorant, muscle relaxant, and anticonvulsive properties. To the best of our knowledge, the promising data regarding the developmental toxicity of guaifenesin are scarce. The current study investigates the developmental toxic effects of guaifenesin in detail using female rats. MATERIALS AND METHODS: Twenty-five dams were divided into five groups. Group 1 served as a control, while Group-2, -3, -4, and -5 were administered with 250, 350, 500, and 600 (mg/kg b.w.) doses of guaifenesin, respectively, starting from gestation day 6 to day 17. Half of the total recovered fetuses was subjected to morphologic and morphometric analysis, while other half was subjected to skeletal examination. RESULTS: A significant reduction in maternal weight, and food/water intake, was observed, however, no mortality and morbidity were observed. About 14 dead fetuses were found in Group-3 and -4 each, while 26 in Group 5. Morphological analysis revealed 21.2%, 45.4%, 67.2%, and 86.9% of total fetuses having hemorrhagic spots in Group-2, -3, -4, and -5, respectively. Dropping wrist/ankle and kinky tail were found in Group-4 and -5 only. Morphometric analysis showed a significant decline in fetal weight, full body length, skull length, forelimb length, hindlimb length, and tail length in all guaifenesin treated groups. Skeletal examination displayed that only Group 5 fetuses had increased intercostal space between 7(th) and 8(th) rib. We also observed improper development of carpals, metacarpals, tarsals, and metatarsals of the Group 5 fetuses. CONCLUSION: Guaifenesin showed a significant developmental toxicity at selected test doses; therefore, a careful use is suggested during pregnancy.
[Mh] Termos MeSH primário: Guaifenesina/toxicidade
Teratogênios/toxicidade
[Mh] Termos MeSH secundário: Animais
Peso Corporal
Feminino
Feto
Masculino
Gravidez
Ratos
Ratos Sprague-Dawley
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Teratogens); 495W7451VQ (Guaifenesin)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160615
[St] Status:MEDLINE
[do] DOI:10.4103/0253-7613.182891


  5 / 455 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26763117
[Au] Autor:Knych HK; Stanley SD; Benson D; Arthur RM
[Ad] Endereço:K.L. Maddy Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California, Davis, CA, USA.
[Ti] Título:Pharmacokinetics of guaifenesin following administration of multiple doses to exercised Thoroughbred horses.
[So] Source:J Vet Pharmacol Ther;39(4):416-9, 2016 Aug.
[Is] ISSN:1365-2885
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Guaifenesin is an expectorant commonly used in performance horses to aid in the clearance of mucus from the airways. Guaifenesin is also a centrally acting skeletal muscle relaxant and as such is a prohibited drug with withdrawal necessary prior to competition. To the authors' knowledge, there are no reports in the literature describing single or multiple oral administrations of guaifenesin in the horse to determine a regulatory threshold and related withdrawal time. Therefore, the objective of the current study was to describe the pharmacokinetics of guaifenesin following oral administration in order to provide data upon which appropriate regulatory recommendations can be established. Nine exercised Thoroughbred horses were administered 2 g of guaifenesin orally BID for a total of five doses. Blood samples were collected immediately prior to drug administration and at various times postadministration. Serum guaifenesin concentrations were determined and pharmacokinetic parameters calculated. Guaifenesin was rapidly absorbed (Tmax of 15 min) following oral administration. The Cmax was 681.3 ± 323.8 ng/mL and 1080 ± 732.8 following the first and last dose, respectively. The serum elimination half-life was 2.62 ± 1.24 h. Average serum guaifenesin concentrations remained above the LOQ of the assay (0.5 ng/mL) by 48 h postadministration of the final dose in 3 of 9 horses.
[Mh] Termos MeSH primário: Expectorantes/farmacocinética
Guaifenesina/farmacocinética
Cavalos/metabolismo
[Mh] Termos MeSH secundário: Administração Oral
Animais
Esquema de Medicação/veterinária
Expectorantes/administração & dosagem
Feminino
Guaifenesina/administração & dosagem
Meia-Vida
Cavalos/sangue
Masculino
Condicionamento Físico Animal
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Expectorants); 495W7451VQ (Guaifenesin)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170607
[Lr] Data última revisão:
170607
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160115
[St] Status:MEDLINE
[do] DOI:10.1111/jvp.12287


  6 / 455 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26686647
[Au] Autor:Melegari C; Bertoni S; Genovesi A; Hughes K; Rajabi-Siahboomi AR; Passerini N; Albertini B
[Ad] Endereço:Department of Pharmacy and BioTechnology, University of Bologna, Via S. Donato 19/2, 40127 Bologna, Italy.
[Ti] Título:Ethylcellulose film coating of guaifenesin-loaded pellets: A comprehensive evaluation of the manufacturing process to prevent drug migration.
[So] Source:Eur J Pharm Biopharm;100:15-26, 2016 Mar.
[Is] ISSN:1873-3441
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The aim of the research was to investigate the complete process of pellet production in a Wurster fluidized bed coater in order to determine the main factors affecting the migration phenomenon of a soluble API through the ethycellulose film coating (Surelease®) and hence the long-term stability of the controlled release pellets. Guaifenesin (GFN), as BCS class I model drug, was layered on sugar spheres using a binder-polymer solution containing the dissolved GFN. The drug loaded pellets were then coated with Surelease®. The influence of drug loading (4.5-20.0% w/w), curing conditions (40-60°C and dynamic-static equipment), coating level (12-20% theoretical weight gain) and composition of the binder-layering solution (hypromellose versus Na alginate) on process efficiency (RSDW%), GFN content uniformity (RSDC%), GFN solid state (DSC and XRD) and pellet release profiles was evaluated. The effectiveness of the Surelease film was strongly affected by the ability of GFN to cross the coating layer and to recrystallize on the pellet surface. Results indicated that this behaviour was dependent on the polymer used in the binder-layering solution. Using hypromellose as polymer, GFN recrystallized on the coated pellet surface at both drug loadings. The curing step was necessary to stabilize the film effectiveness at the higher drug loading. Increasing the coating level delayed but did not prevent the GFN diffusion. Replacing hypromellose with Na alginate, reduced the migration of GFN through the film to a negligible amount even after six months of storage and the curing step was not necessary to achieve stable controlled release profiles over storage.
[Mh] Termos MeSH primário: Celulose/análogos & derivados
Química Farmacêutica/métodos
Implantes de Medicamento/síntese química
Guaifenesina/síntese química
[Mh] Termos MeSH secundário: Celulose/síntese química
Celulose/farmacocinética
Implantes de Medicamento/farmacocinética
Liberação Controlada de Fármacos
Guaifenesina/farmacocinética
Difração de Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Implants); 495W7451VQ (Guaifenesin); 7Z8S9VYZ4B (ethyl cellulose); 9004-34-6 (Cellulose)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:170103
[Lr] Data última revisão:
170103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151222
[St] Status:MEDLINE


  7 / 455 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26632082
[Au] Autor:Thompson GA; Solomon G; Albrecht HH; Reitberg DP; Guenin E
[Ad] Endereço:GA Thompson Consulting, LLC, West Chester, OH, USA.
[Ti] Título:Guaifenesin Pharmacokinetics Following Single-Dose Oral Administration in Children Aged 2 to 17 Years.
[So] Source:J Clin Pharmacol;56(7):894-901, 2016 07.
[Is] ISSN:1552-4604
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This study characterized guaifenesin pharmacokinetics in children aged 2 to 17 years (n = 40) who received a single oral dose of guaifenesin (age-based doses of 100-400 mg) 2 hours after breakfast. Plasma samples were obtained before and for 8 hours after dosing and analyzed for guaifenesin using liquid chromatography-tandem mass spectrometry. Pharmacokinetic parameters were estimated using noncompartmental methods, relationships with age were assessed using linear regression, and dose proportionality was assessed on 95% confidence intervals. Based on the upper dose recommended in the monograph (for both children and adolescents), area under the curve from time zero to infinity and maximum plasma concentration both increased with age. However, when comparing the upper dose for children aged 2 to 11 years with the lower dose for adolescents aged 12 to 17 years, similar systemic exposure was observed. As expected due to increasing body size, oral clearance (CLo ) and terminal volume of distribution (Vz /F) increased with age. Due to a larger increase in Vz /F than CLo , an increase in terminal exponential half-life was also observed. Allometric scaling indicated no maturation-related changes in CLo and Vz /F.
[Mh] Termos MeSH primário: Expectorantes/administração & dosagem
Expectorantes/farmacocinética
Guaifenesina/administração & dosagem
Guaifenesina/farmacocinética
[Mh] Termos MeSH secundário: Administração Oral
Adolescente
Fatores Etários
Área Sob a Curva
Criança
Pré-Escolar
Feminino
Seres Humanos
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Expectorants); 495W7451VQ (Guaifenesin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151204
[St] Status:MEDLINE
[do] DOI:10.1002/jcph.682


  8 / 455 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26254602
[Au] Autor:Yehia AM; Mohamed HM
[Ad] Endereço:Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr Al-Aini St., 11562 Cairo, Egypt.
[Ti] Título:Chemometrics resolution and quantification power evaluation: Application on pharmaceutical quaternary mixture of Paracetamol, Guaifenesin, Phenylephrine and p-aminophenol.
[So] Source:Spectrochim Acta A Mol Biomol Spectrosc;152:491-500, 2016 Jan 05.
[Is] ISSN:1873-3557
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Three advanced chemmometric-assisted spectrophotometric methods namely; Concentration Residuals Augmented Classical Least Squares (CRACLS), Multivariate Curve Resolution-Alternating Least Squares (MCR-ALS) and Principal Component Analysis-Artificial Neural Networks (PCA-ANN) were developed, validated and benchmarked to PLS calibration; to resolve the severely overlapped spectra and simultaneously determine; Paracetamol (PAR), Guaifenesin (GUA) and Phenylephrine (PHE) in their ternary mixture and in presence of p-aminophenol (AP) the main degradation product and synthesis impurity of Paracetamol. The analytical performance of the proposed methods was described by percentage recoveries, root mean square error of calibration and standard error of prediction. The four multivariate calibration methods could be directly used without any preliminary separation step and successfully applied for pharmaceutical formulation analysis, showing no excipients' interference.
[Mh] Termos MeSH primário: Acetaminofen/análise
Aminofenóis/análise
Analgésicos não Entorpecentes/análise
Expectorantes/análise
Guaifenesina/análise
Descongestionantes Nasais/análise
Fenilefrina/análise
[Mh] Termos MeSH secundário: Combinação de Medicamentos
Contaminação de Medicamentos
Análise dos Mínimos Quadrados
Análise Multivariada
Redes Neurais (Computação)
Análise de Componente Principal
Espectrofotometria/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aminophenols); 0 (Analgesics, Non-Narcotic); 0 (Drug Combinations); 0 (Expectorants); 0 (Nasal Decongestants); 1WS297W6MV (Phenylephrine); 362O9ITL9D (Acetaminophen); 495W7451VQ (Guaifenesin); R7P8FRP05V (4-aminophenol)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150810
[St] Status:MEDLINE


  9 / 455 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26477321
[Au] Autor:Ohta Y; Nishi S; Hasegawa R; Hatada Y
[Ad] Endereço:Japan Agency for Marine-Earth Science and Technology (JAMSTEC), 2-15 Natsushima, Yokosuka, Kanagawa, Japan.
[Ti] Título:Combination of six enzymes of a marine Novosphingobium converts the stereoisomers of ß-O-4 lignin model dimers into the respective monomers.
[So] Source:Sci Rep;5:15105, 2015 Oct 19.
[Is] ISSN:2045-2322
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Lignin, an aromatic polymer of phenylpropane units joined predominantly by ß-O-4 linkages, is the second most abundant biomass component on Earth. Despite the continuous discharge of terrestrially produced lignin into marine environments, few studies have examined lignin degradation by marine microorganisms. Here, we screened marine isolates for ß-O-4 cleavage activity and determined the genes responsible for this enzymatic activity in one positive isolate. Novosphingobium sp. strain MBES04 converted all four stereoisomers of guaiacylglycerol-ß-guaiacyl ether (GGGE), a structural mimic of lignin, to guaiacylhydroxypropanone as an end metabolite in three steps involving six enzymes, including a newly identified Nu-class glutathione-S-transferase (GST). In silico searches of the strain MBES04 genome revealed that four GGGE-metabolizing GST genes were arranged in a cluster. Transcriptome analysis demonstrated that the lignin model compounds GGGE and (2-methoxyphenoxy)hydroxypropiovanillone (MPHPV) enhanced the expression of genes in involved in energy metabolism, including aromatic-monomer assimilation, and evoked defense responses typically expressed upon exposure to toxic compounds. The findings from this study provide insight into previously unidentified bacterial enzymatic systems and the physiological acclimation of microbes associated with the biological transformation of lignin-containing materials in marine environments.
[Mh] Termos MeSH primário: Proteínas de Bactérias/metabolismo
Enzimas/metabolismo
Lignina/metabolismo
Sphingomonadaceae/enzimologia
[Mh] Termos MeSH secundário: Proteínas de Bactérias/genética
Catálise
Enzimas/genética
Regulação Bacteriana da Expressão Gênica
Ordem dos Genes
Loci Gênicos
Glutationa Transferase/metabolismo
Guaifenesina/análogos & derivados
Guaifenesina/metabolismo
Lignina/química
Sphingomonadaceae/genética
Estereoisomerismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (Enzymes); 495W7451VQ (Guaifenesin); 7382-59-4 (guaiacylglycerol-beta-guaiacyl ether); 9005-53-2 (Lignin); EC 2.5.1.18 (Glutathione Transferase)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151020
[St] Status:MEDLINE
[do] DOI:10.1038/srep15105


  10 / 455 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:26462765
[Au] Autor:Bennett WD; Kala A; Duckworth H; Zeman KL; Wu J; Henderson A; Yopp M; Rubin BK
[Ad] Endereço:Center for Environmental Medicine, Asthma, and Lung Biology, University of North Carolina at Chapel Hill, USA; Dept of Medicine, University of North Carolina at Chapel Hill, USA. Electronic address: William_Bennett@med.unc.edu.
[Ti] Título:Effect of a single 1200 Mg dose of Mucinex® on mucociliary and cough clearance during an acute respiratory tract infection.
[So] Source:Respir Med;109(11):1476-83, 2015 Nov.
[Is] ISSN:1532-3064
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Observational studies suggest that orally administered guaifenesin (GGE) may thin lower respiratory tract secretions but none have examined its effects on mucociliary and cough clearance (MCC/CC) during a respiratory tract infection (RTI). The current study was a randomized, parallel-group, double-blind, placebo-controlled study in non-smoking adults who suffered from an acute upper RTI. METHODS: We assessed the effects of a single dose of Mucinex(®) 1200 mg (2 × 600 mg extended release tablets) (ER GGE) on 1) MCC/CC by assessing the rate of removal from the lung of inhaled radioactive tracer particles (Tc99m-sulfur colloid), 2) sputum dynamic rheology by stress/strain creep transformation over the linear part of the curve, 3) sessile drop interfacial tension by the deNouy ring technique, and 4) subjective symptom measures. MCC was measured during the morning (period 1) and compared to that in the afternoon 4 h later (period 2) immediately following either drug (n = 19) or placebo (n = 19). For both period 1 and 2 subjects performed 60 voluntary coughs from 60 to 90 min after inhalation of radio-labeled aerosol for a measure of CC. Sputum properties were measured from subjects who expectorated sputum during the cough period post treatment (n = 8-12 for each cohort). RESULTS: We found no effect of ER GGE on MCC or CC compared to placebo. MCC through 60 min for period 1 vs. 2 = 8.3 vs. 11.8% (placebo) and = 9.7 vs. 11.1% (drug) (NS) and CC for period 1 vs. 2 was 9.9 vs. 9.1% (placebo) and 10.8 vs. 5.6% (drug) (NS). There was no significant difference in sputum biophysical properties after administration of drug or placebo. CONCLUSIONS: There was no significant effect of a single dose of ER GGE on MCC/CC or on sputum biophysical properties compared to placebo in this population of adult patients with an acute RTI. ClinicalTrials.gov Identifier: NCT01114581.
[Mh] Termos MeSH primário: Tosse/tratamento farmacológico
Expectorantes/uso terapêutico
Guaifenesina/uso terapêutico
Depuração Mucociliar/efeitos dos fármacos
Infecções Respiratórias/tratamento farmacológico
[Mh] Termos MeSH secundário: Doença Aguda
Administração Oral
Adulto
Tosse/microbiologia
Método Duplo-Cego
Expectorantes/farmacocinética
Expectorantes/farmacologia
Feminino
Guaifenesina/farmacocinética
Guaifenesina/farmacologia
Seres Humanos
Masculino
Meia-Idade
Infecções Respiratórias/complicações
Infecções Respiratórias/fisiopatologia
Reologia
Escarro/química
Escarro/efeitos dos fármacos
Escarro/fisiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Expectorants); 495W7451VQ (Guaifenesin)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:151109
[Lr] Data última revisão:
151109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151015
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE



página 1 de 46 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde